Atlas Trials

DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

Clinical trial NCT05755360 · COMPLETED

Trial details

NCT number
NCT05755360
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Study type
OBSERVATIONAL
Diabetes Mellitus, Type 2
Start date
2023-02-21
Primary completion
2024-10-21
Enrollment
291

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.